Lifecore Biomedical (LFCR) news
Recent news
LifeCore Biomedical reaffirms revenue and adj EBITDA guidance for calendar year 2026
AInvest Wire · Aug 5, 2026LifeCore Biomedical Q2 2026 revenues $34.20 mln, down 6.2% from prior year
AInvest Wire · Aug 5, 2026LifeCore Biomedical 2Q adj. EBITDA $8.57M
LifeCore Biomedical reported adjusted EBITDA of $8.57 million for the second quarter of fiscal 2026, reflecting a notable improvement in its financial performance compared to recent periods. This result marks a significant turnaround for the company, which has been undergoing strategic…
AInvest Wire · Aug 5, 2026LifeCore Biomedical signs three new customer agreements
Lifecore Biomedical, Inc. (NASDAQ: LFCR) has entered into three new commercial agreements with its long-term customer, Alcon (SIX/NYSE: ALC), as part of an expanded partnership. The agreements include an 8-year extension of its contract manufacturing arrangement, an amendment to its Hyaluronic Acid…
AInvest Wire · Jul 28, 2026LifeCore announces inducement grant under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jul 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.